"WASHINGTON, DC â€” The FDA is investigating the significant increase in major adverse cardiac events (MACE) seen for the everolimus-eluting bioresorbable vascular scaffold (Absorb BVS, Abbott Vascular) vs everolimus-eluting metal stent ("...
(Generic versions may still be available.)
(dipyridamole USP) Prescribing Information
Persantine® (dipyridamole USP) for intravenous injection is a coronary vasodilator described as 2,6-Bis(diethanolamino)-4,8-dipiperidinopy-rimido [5,4-d]-pyrimidine.
IV Persantine® as a sterile solution for intravenous administration contains:
Active Ingredient VIAL10 mL: dipyridamole USP 50 mg.
Inactive Ingredients VIAL10 mL: polyethylene glycol 600 500 mg, tartaric acid 20 mg. pH is adjusted to 2.7 ±0.5 with hydrochloric acid.
What are the precautions when taking persantine (Persantine IV)?
Last reviewed on RxList: 11/30/2016
This monograph has been modified to include the generic and brand name in many instances.
Additional Persantine IV Information
- Persantine IV Drug Interactions Center: dipyridamole iv
- Persantine IV Side Effects Center
- Persantine IV Overview including Precautions
- Persantine IV FDA Approved Prescribing Information including Dosage
Persantine IV - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.